Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adma Biologics (NQ: ADMA )

11.45 -0.41 (-3.46%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,176,385
Open 12.10
Bid (Size) 11.60 (1)
Ask (Size) 12.10 (4)
Prev. Close 11.86
Today's Range 11.42 - 12.17
52wk Range 3.060 - 14.03
Shares Outstanding 196,357,149
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82
On Tuesday, Avadel Pharmaceuticals stock received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82. 
Via Investor's Business Daily
ADMA Biologics to Report Second Quarter 2024 Financial Results on August 8, 2024
Conference Call Scheduled for August 8, 2024, at 4:30 p.m. ET 
From ADMA Biologics, Inc.
Via GlobeNewswire

Performance

YTD
+151.65%
+151.65%
1 Month
-1.63%
-1.63%
3 Month
+66.91%
+66.91%
6 Month
+121.04%
+121.04%
1 Year
+176.57%
+176.57%

More News

Read More
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
Via Investor's Business Daily
Beam Therapeutics Stock Earns RS Rating Jump To 85
Via Investor's Business Daily
Jim Cramer Recommends Not Selling Vertiv, Says Buy This Social Media Stock 'Hand Over Fist'
Via Benzinga
How Is The Market Feeling About ADMA Biologics?
Via Benzinga
Expert Ratings For ADMA Biologics
Via Benzinga
Leslie's Issues Preliminary Financial Results, Joins Beyond Meat, Domino's And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Biotech Arvinas Stock Earns 82 RS Rating
Via Investor's Business Daily
Denali Therapeutics Stock Gets Technical Rating Upgrade
Via Investor's Business Daily
3 Millionaire-Making Stock Picks With Astounding Growth Potential
Via InvestorPlace
Bull Run Alert: 3 Stocks Set to Soar in the Coming Months
Via InvestorPlace
Peeling Back The Layers: Exploring ADMA Biologics Through Analyst Insights
Via Benzinga
ADMA Biologics Analysts Increase Their Forecasts After Upbeat Results
Via Benzinga
UroGen Pharma Stock Earns 91 RS Rating
Via Investor's Business Daily
Arcellx Stock Earns Relative Strength Rating Upgrade
Via Investor's Business Daily
Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
Via Investor's Business Daily
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
Via Investor's Business Daily
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
Via Investor's Business Daily
Krystal Biotech Stock Sees RS Rating Jump To 91
Via Investor's Business Daily
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Genpact Posts Upbeat Earnings, Joins Groupon, Natera, Funko, CarGurus And Other Big Stocks Moving Higher On Friday
Via Benzinga
ADMA Stock Earnings: ADMA Biologics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.